GO:0004905 type I interferon receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004905 defines the molecular function of binding type I interferons (IFN-alpha, beta, delta, epsilon, zeta, kappa, tau, omega) and transmitting signals across the membrane.
• The receptor is a heterodimer of IFNAR1 and IFNAR2, which activates JAK-STAT signaling to induce interferon-stimulated genes.
• Type I interferon receptor activity is critical for antiviral defense, immune regulation, and cancer immunosurveillance.
• Dysregulated type I interferon signaling contributes to autoimmune diseases like systemic lupus erythematosus and systemic sclerosis.
• Anifrolumab, a monoclonal antibody targeting IFNAR1, is approved for SLE and under investigation for systemic sclerosis.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect receptor subunit-specific functions in disease.
Description
Type I interferon receptor activity (GO:0004905) is a molecular function that enables cells to sense and respond to type I interferons, a family of cytokines including IFN-alpha, IFN-beta, and others. This activity is mediated by the heterodimeric receptor composed of IFNAR1 and IFNAR2 subunits, which together bind type I interferons and initiate intracellular signaling cascades. The receptor is expressed on nearly all nucleated cells and plays a central role in antiviral immunity, cell growth regulation, and immune modulation. Researchers study this activity to understand how cells coordinate defense against pathogens and how its dysregulation leads to autoimmune diseases and cancer. The clinical success of anifrolumab, an anti-IFNAR1 antibody, underscores the therapeutic relevance of targeting this receptor activity.
type I interferon receptor activity At A Glance
| GO ID | GO:0004905 |
|---|---|
| GO term | type I interferon receptor activity |
| Ontology | molecular_function |
| Synonym | interferon-alpha/beta receptor activity, interferon-alpha receptor activity, interferon-beta receptor activity, interferon-delta receptor activity, interferon-epsilon receptor activity, interferon-kappa receptor activity, interferon-omega receptor activity, interferon-tau receptor activity, interferon-zeta receptor activity, type I IFN receptor activity |
| Major function | Binding type I interferons and transmitting signals across the membrane to initiate cellular responses |
| Receptor composition | Heterodimer of IFNAR1 and IFNAR2 subunits |
| Ligand specificity | Type I interferons including IFN-alpha, IFN-beta, IFN-delta, IFN-epsilon, IFN-zeta, IFN-kappa, IFN-tau, and IFN-omega |
| Downstream signaling | Activation of JAK-STAT pathway, leading to induction of interferon-stimulated genes |
What Is GO:0004905?
According to the Gene Ontology, type I interferon receptor activity (GO:0004905) is defined as combining with a type I interferon and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families. This activity is a molecular function that involves ligand binding and signal transduction across the plasma membrane.
Why Is type I interferon receptor activity Important in Cell Biology?
Type I interferon receptor activity is essential for host defense against viral infections and for shaping immune responses. It is the first step in the type I interferon signaling cascade, which induces hundreds of interferon-stimulated genes that inhibit viral replication and modulate cell proliferation and apoptosis. Dysregulation of this receptor activity is implicated in autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis, where chronic interferon signaling contributes to tissue damage. In cancer, type I interferon receptor signaling influences immune surveillance and response to immune checkpoint blockade. Therefore, understanding this molecular function is critical for developing therapies that either enhance antiviral immunity or dampen pathological interferon signaling.
• Mediates antiviral defense by inducing interferon-stimulated genes that restrict viral replication.
• Regulates immune cell functions, including NK cell interferon-gamma production.
• Plays a role in cancer immunosurveillance and response to immune checkpoint inhibitors.
• Contributes to the pathogenesis of autoimmune diseases like SLE and systemic sclerosis.
• Targeted by anifrolumab, a therapeutic antibody approved for SLE and in trials for systemic sclerosis.
• Involved in abdominal aortic aneurysm formation, as shown by IFNAR1 deletion studies.
• Modulates T cell signaling through TRAF3 and PTPN22.
• Can be modulated by soluble recombinant receptors with antiviral activity.
• Influenced by cellular factors such as Skp2 and ceftazidime.
• Serves as a model for studying receptor tyrosine kinase-like signaling and JAK-STAT activation.
Molecular Mechanism of type I interferon receptor activity
Ligand Binding and Receptor Dimerization
In simple terms: Type I interferons bind to the receptor on the cell surface, causing two receptor subunits to come together.
Type I interferon receptor activity begins with the binding of a type I interferon molecule to the extracellular domains of IFNAR1 and IFNAR2. This binding induces conformational changes that bring the two subunits into a productive heterodimeric complex, enabling signal transduction across the plasma membrane. The receptor exhibits broad ligand specificity, recognizing multiple type I interferon subtypes including IFN-alpha and IFN-beta.
JAK Activation and STAT Phosphorylation
In simple terms: Once the receptor subunits are together, they activate enzymes called JAKs, which then add phosphate groups to STAT proteins.
The heterodimeric receptor is associated with Janus kinases (JAKs), specifically JAK1 and TYK2. Upon ligand-induced dimerization, these kinases phosphorylate each other and then phosphorylate tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2. These phosphotyrosine motifs serve as docking sites for STAT proteins, particularly STAT1 and STAT2, which are subsequently phosphorylated. This step is critical for transmitting the signal from the membrane to the nucleus.
Formation of ISGF3 and Gene Transcription
In simple terms: Phosphorylated STATs combine with another protein to form a complex that enters the nucleus and turns on antiviral genes.
Phosphorylated STAT1 and STAT2 form a heterodimer that associates with IRF9 to create the ISGF3 (interferon-stimulated gene factor 3) complex. This complex translocates to the nucleus and binds to interferon-stimulated response elements (ISREs) in the promoters of interferon-stimulated genes, initiating their transcription. The resulting proteins mediate antiviral, antiproliferative, and immunomodulatory effects.
Negative Regulation and Signal Attenuation
In simple terms: The cell has brakes to stop the interferon signal so it doesn't overreact.
To prevent excessive signaling, type I interferon receptor activity is tightly regulated by negative feedback mechanisms. Phosphatases such as PTPN22 can dephosphorylate JAKs and STATs, dampening the signal. TRAF3 has been shown to enhance type I interferon receptor signaling in T cells by modulating PTPN22. Additionally, SOCS proteins and ubiquitin ligases target receptor components for degradation, ensuring transient signaling.
Cross-talk with Other Signaling Pathways
In simple terms: The interferon receptor signal can interact with other cellular pathways to fine-tune responses.
Type I interferon receptor activity intersects with various signaling cascades, including autophagy and metabolic pathways. For instance, recombinant soluble type I interferon receptor can induce autophagy-related proteins to exert antiviral activity. Furthermore, cellular factors like Skp2 modulate type I interferon activity, and ceftazidime reduces Skp2 to promote interferon signaling. These cross-talk mechanisms expand the functional repertoire of the receptor.
Key Genes Involved in GO:0004905 type I interferon receptor activity
The following genes and proteins are central to type I interferon receptor activity, including receptor subunits, signaling kinases, transcription factors, and regulatory molecules.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNAR1 | Type I interferon receptor subunit 1; binds interferons and forms heterodimer with IFNAR2 | Target of anifrolumab; knockout attenuates abdominal aortic aneurysm in mice |
| IFNAR2 | Type I interferon receptor subunit 2; high-affinity ligand binding and signal transduction | Essential for receptor function; mutations affect interferon responses |
| JAK1 | Janus kinase 1; phosphorylates STAT proteins upon receptor activation | Key mediator of interferon signaling; knockout abolishes responses |
| TYK2 | Tyrosine kinase 2; associates with IFNAR1 and phosphorylates STATs | Required for type I interferon signaling; mutations linked to autoimmunity |
| STAT1 | Signal transducer and activator of transcription 1; forms ISGF3 complex | Critical for interferon-stimulated gene induction |
| STAT2 | Signal transducer and activator of transcription 2; partner of STAT1 | Essential for antiviral responses; deficiency causes susceptibility to viral infections |
| IRF9 | Interferon regulatory factor 9; completes ISGF3 complex | Mediates transcriptional activation of ISGs |
| PTPN22 | Protein tyrosine phosphatase, non-receptor type 22; negatively regulates interferon signaling | Modulated by TRAF3; risk gene for autoimmunity |
| TRAF3 | TNF receptor associated factor 3; enhances type I interferon receptor signaling in T cells | Regulates PTPN22; links interferon signaling to T cell function |
| SOCS1 | Suppressor of cytokine signaling 1; negative feedback inhibitor of JAK-STAT | Limits interferon responses; knockout causes hyperinflammation |
| SOCS3 | Suppressor of cytokine signaling 3; inhibits JAK activity | Attenuates interferon signaling; involved in immune regulation |
| USP18 | Ubiquitin specific peptidase 18; negative regulator of interferon signaling | Prevents excessive interferon responses; knockout lethal |
| ISG15 | Interferon-stimulated gene 15; ubiquitin-like modifier | Effector of interferon responses; involved in antiviral defense |
| MX1 | Myxovirus resistance 1; GTPase with antiviral activity | Classic interferon-stimulated gene; marker of receptor activity |
| OAS1 | 2'-5'-oligoadenylate synthetase 1; activates RNase L | Mediates antiviral effects of interferons |
| PKR | Protein kinase R; inhibits translation upon dsRNA binding | Interferon-induced antiviral effector |
| IFIH1 | Interferon induced with helicase C domain 1 (MDA5); cytosolic RNA sensor | Induces type I interferons; linked to autoimmune diseases |
| TMEM173 | Stimulator of interferon genes (STING); adaptor in cytosolic DNA sensing | Activates type I interferon production; target for cancer immunotherapy |
How Is type I interferon receptor activity Regulated?
Type I interferon receptor activity is regulated at multiple levels. Ligand availability, receptor expression levels, and post-translational modifications of receptor subunits influence signal strength. Negative feedback loops involving SOCS proteins, phosphatases like PTPN22, and ubiquitin ligases ensure transient signaling. TRAF3 enhances receptor signaling in T cells by modulating PTPN22. Additionally, cellular factors such as Skp2 can promote type I interferon activity, and pharmacological agents like ceftazidime can reduce Skp2 to enhance interferon responses. Soluble forms of the receptor can act as decoys or agonists, modulating antiviral activity.
type I interferon receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNAR1 | Systemic lupus erythematosus; systemic sclerosis; abdominal aortic aneurysm | Knockout mice, anti-IFNAR1 antibody treatment |
| IFNAR2 | Antiviral immunity; autoimmune diseases | Knockout mice, soluble receptor overexpression |
| STAT1 | Mendelian susceptibility to mycobacterial disease; autoimmunity | Knockout and knock-in mice |
| TRAF3 | T cell signaling; autoimmunity | T cell-specific knockout |
| PTPN22 | Autoimmune diseases (type 1 diabetes, rheumatoid arthritis) | Knockout and point mutation models |
Systemic Lupus Erythematosus (SLE)
SLE is characterized by chronic activation of type I interferon signaling. Anifrolumab, a monoclonal antibody that binds IFNAR1 and blocks type I interferon receptor activity, has shown efficacy in clinical trials for SLE, reducing disease activity. This validates the receptor as a therapeutic target and highlights the importance of understanding its function in autoimmune pathogenesis.
Systemic Sclerosis
Systemic sclerosis is an autoimmune disease with fibrosis and vascular damage, often associated with elevated type I interferon signatures. The DAISY study is evaluating anifrolumab, an anti-IFNAR1 antibody, in systemic sclerosis, based on the rationale that blocking type I interferon receptor activity may reduce fibrosis and inflammation.
Cancer and Immune Checkpoint Blockade
Type I interferon receptor signaling in melanoma cells induces cell-intrinsic PD-1 expression, which can antagonize immune checkpoint blockade. This suggests that modulating receptor activity may influence responses to cancer immunotherapy. Understanding how receptor activity shapes the tumor microenvironment is an active area of research.
Abdominal Aortic Aneurysm (AAA)
Deletion of IFNAR1, a subunit of the type I interferon receptor, attenuates experimental abdominal aortic aneurysm formation in mice. This indicates that type I interferon receptor activity contributes to vascular remodeling and inflammation in AAA, providing a potential target for intervention.
From type I interferon receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of IFNAR1 deletion on immune cell function? | IFNAR1 knockout mice or cell lines |
| How does a specific point mutation in IFNAR2 affect ligand binding? | CRISPR knock-in of point mutations in IFNAR2 |
| Can soluble type I interferon receptor inhibit viral replication? | Overexpression of soluble IFNAR in cell culture |
| How does IFNAR1 degradation affect interferon signaling? | Knock-in of tagged IFNAR1 for imaging |
| What is the role of TRAF3 in T cell interferon signaling? | T cell-specific TRAF3 knockout |
| Does blocking IFNAR1 ameliorate autoimmune disease? | Humanized mouse models or clinical trials with anifrolumab |
How to Study the type I interferon receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identifying ISGs induced by receptor activity |
| Phosphoproteomics | Phosphorylation of signaling proteins | Mapping JAK-STAT activation |
| Western blot | Protein levels and phosphorylation | Validating STAT1/STAT2 activation |
| Immunofluorescence | Subcellular localization of receptor subunits | Visualizing receptor internalization |
| Antiviral assay | Inhibition of viral replication | Testing soluble receptor efficacy |
| Flow cytometry | Surface expression of IFNAR1/2 | Quantifying receptor levels on immune cells |
| CRISPR screening | Identification of genes modulating receptor activity | Genome-wide screens for interferon regulators |
Transcriptomic Analysis of Interferon-Stimulated Genes
RNA sequencing (RNA-seq) is widely used to measure the expression of interferon-stimulated genes (ISGs) following type I interferon receptor activation. This method provides a global view of transcriptional responses and can identify novel ISGs. It is particularly useful for comparing wild-type and receptor-mutant cells.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status upon receptor activation. This approach identifies signaling intermediates and feedback regulators, such as STAT phosphorylation and SOCS induction.
Imaging Receptor Dynamics
Fluorescence microscopy and live-cell imaging of tagged receptor subunits (e.g., GFP-IFNAR1) allow visualization of receptor trafficking, dimerization, and internalization. These methods reveal spatiotemporal aspects of receptor activity.
Functional Assays for Antiviral Activity
Antiviral assays measure the ability of type I interferon receptor activity to inhibit viral replication. Plaque reduction assays and viral titer measurements are common. Soluble receptor constructs can be tested for their ability to induce antiviral states.
How CRISPR Can Be Used to Study GO:0004905 type I interferon receptor activity
Knockout
CRISPR knockout of IFNAR1, IFNAR2, JAK1, or TYK2 completely abolishes type I interferon receptor activity, providing a clean background to study downstream effects. For example, IFNAR1 knockout mice are used to study abdominal aortic aneurysm, and knockout of IFNAR1 in NK cells reveals its role in negatively regulating interferon-gamma production.
Point Mutation
CRISPR-mediated point mutations can mimic naturally occurring variants or disrupt specific phosphorylation sites in receptor subunits or signaling molecules. This allows precise dissection of residues required for ligand binding, JAK activation, or STAT docking, as demonstrated for PTPN22 modulation by TRAF3.
Knock-in
Knock-in of tagged versions of IFNAR1 or IFNAR2 (e.g., GFP or HA tags) enables real-time imaging and biochemical purification of receptor complexes. This approach helps track receptor trafficking and interaction partners under physiological conditions.
Overexpression
Overexpression of wild-type or mutant receptor subunits, or of soluble decoy receptors, can amplify or inhibit type I interferon signaling. Soluble type I interferon receptor overexpression has been shown to exert antiviral activity by inducing autophagy-related proteins. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports type I interferon receptor activity Research
Researchers studying type I interferon receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, immune regulation, or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for type I interferon receptor activity research.
Frequently Asked Questions About type I interferon receptor activity
What is type I interferon receptor activity?
Type I interferon receptor activity (GO:0004905) is the molecular function of binding type I interferons and transmitting signals across the cell membrane to initiate cellular responses.
What genes are involved in type I interferon receptor activity?
Key genes include IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT2, IRF9, and regulatory genes like PTPN22 and TRAF3.
What diseases are associated with type I interferon receptor activity?
Dysregulation is linked to systemic lupus erythematosus, systemic sclerosis, abdominal aortic aneurysm, and cancer.
How is type I interferon receptor activity studied?
Common methods include RNA-seq, phosphoproteomics, Western blot, immunofluorescence, antiviral assays, and CRISPR screens.
What is the role of IFNAR1 in type I interferon receptor activity?
IFNAR1 is a subunit of the receptor; it binds interferons and is targeted by the therapeutic antibody anifrolumab.
Can type I interferon receptor activity be inhibited therapeutically?
Yes, anifrolumab blocks IFNAR1 and is approved for SLE and in trials for systemic sclerosis.
What is the difference between type I and type II interferon receptors?
Type I receptors bind IFN-alpha/beta family cytokines, while type II receptors bind IFN-gamma; they are distinct molecular functions.
How does TRAF3 regulate type I interferon receptor signaling?
TRAF3 enhances signaling in T cells by modulating the phosphatase PTPN22.
What is the role of soluble type I interferon receptor?
Soluble receptors can act as decoys or agonists; recombinant soluble receptor exerts antiviral activity by inducing autophagy.
How can CRISPR be used to study type I interferon receptor activity?
CRISPR knockout, knock-in, point mutation, and overexpression models enable precise dissection of receptor subunit functions and signaling.
Conclusion
Type I interferon receptor activity (GO:0004905) is a fundamental molecular function that mediates cellular responses to type I interferons, with critical roles in antiviral immunity, autoimmune disease, and cancer. The heterodimeric IFNAR1/IFNAR2 receptor activates JAK-STAT signaling to induce interferon-stimulated genes, and its dysregulation is targeted by therapeutics like anifrolumab. Continued research using CRISPR models and advanced omics will further elucidate its mechanisms and therapeutic potential.
References
- 1. Morand EF et al.. 2020. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.. N Engl J Med 382(3):211-221 PMID: 31851795
- 2. Khanna D et al.. 2024. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.. Clin Exp Rheumatol 42(8):1635-1644 PMID: 39152751
- 3. Shoji T et al.. 2022. Type I Interferon Receptor Subunit 1 Deletion Attenuates Experimental Abdominal Aortic Aneurysm Formation.. Biomolecules 12(10) PMID: 36291750
- 4. Lee AJ et al.. 2019. Type I Interferon Receptor on NK Cells Negatively Regulates Interferon-γ Production.. Front Immunol 10:1261 PMID: 31214198
- 5. Aliaga-Gaspar P et al.. 2024. Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.. Biomed Pharmacother 181:117678 PMID: 39577364
- 6. Qiao C et al.. 2023. Ceftazidime reduces cellular Skp2 to promote type-I interferon activity.. Immunology 170(4):527-539 PMID: 37641430
- 7. Holzgruber J et al.. 2024. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade.. Nat Commun 15(1):7165 PMID: 39187481
- 8. Hornick EL et al.. 2022. TRAF3 enhances type I interferon receptor signaling in T cells by modulating the phosphatase PTPN22.. Sci Signal 15(753):eabn5507 PMID: 36166512
